Physician profile
Theodore Nyquist
NPI 1609972926
$5,358.76
in general payments reported to CMS, 2019-2025
46 companies · $558 in 2025
The $558 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,341 · 2020: $189 · 2021: $402 · 2022: $606 · 2023: $1,062 · 2024: $1,201 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,820.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $558.13 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $553.77 | 2019-2024 | |
| Novo Nordisk INC | $544.67 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $473.62 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Pfizer INC. | $412.99 | 2019-2025 | |
| Glaxosmithkline, LLC. | $278.66 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $269.81 | 2022-2024 | |
| Amgen INC. | $246.33 | 2019-2023 | Otezla, Repatha |
| E.R. Squibb & Sons, L.L.C. | $237.93 | 2019-2023 | Camzyos |
| Otsuka America Pharmaceutical, INC. | $190.03 | 2019-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $149.86 | 2019-2022 | |
| Exact Sciences Corporation | $132.85 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $115.06 | 2019-2025 | Proquad, Enflonsia, Capvaxive |
| Abbott Laboratories | $113.66 | 2022-2024 | Freestyle Libre 3, Proclaim |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $101.70 | 2022-2024 | Caplyta |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Nyquist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.